FDA approves SC delivery of Takeda’s Entyvio for Crohn’s disease
Takeda has received the US Food and Drug Administration (FDA) approval for the subcutaneous (SC) administration of Entyvio (vedolizumab) to treat certain type of Crohn’s disease patients. The